The investment, which the foundation says is its largest in women’s health, will support research in maternal health, obstetric care and sexually transmitted infections, among other areas.

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment The success of Vertex’s opioid alternative Journavx could aid a group of biotechs that aim to take a similar ...

Venture firm Frazier closes $1.3B fund for early-stage biotech investing Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Regeneron cancer bispecific rejected again; Allogene discloses trial death The FDA issued a complete response letter for Regeneron’s lymphoma drug odronextamab. Meanwhile, Allogene is adjusting its ...

Organon’s experimental treatment for endometriosis failed to improve pelvic pain for women in a Phase 2 study, leading the company to give up on the drug. The trial tested three oral doses of OG-6219 ...

The latest clinical trial news for biotech and biopharmaceutical professionals ...

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure Less than two weeks after stepping down, Prasad will return to lead the agency office overseeing vaccines and gene therapy “at ...

Experts ousted from CDC panel warn of damage to US vaccine policy The 17 advisers fired in June by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further degradation in vaccine ...

HHS abandons mRNA vaccine research BARDA will cancel nearly $500 million worth of contracts supporting the development of mRNA shots, which proved vital during the COVID pandemic.

Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline. In ...

Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug The smaller market now envisioned for vepdegestrant has changed both companies’ stance on a deal that granted each an equal share of the ...